Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 18;16(8):7131-7140.
doi: 10.18632/aging.205747. Epub 2024 Apr 18.

Treatment patterns and survival in T4b esophageal cancer: a retrospective cohort study

Bin-Bin Yu  1 , Jiang-Qiong Huang  1 , Huan-Wei Liang  1 , Yang Liu  1 , Long Chen  1 , Su Pei  1 , Wei Huang  1 , Xin-Bin Pan  1
Affiliations

Treatment patterns and survival in T4b esophageal cancer: a retrospective cohort study

Bin-Bin Yu et al. Aging (Albany NY). .

Abstract

Purpose: This study aims to evaluate the efficacy of various treatment approaches in stage T4b esophageal cancer patients.

Materials and methods: Data were extracted from the Surveillance, Epidemiology, and End Results databases, covering patients diagnosed with esophageal cancer between 2000 and 2020. Kaplan-Meier analysis was used to assess cancer-specific survival (CSS) and overall survival (OS) across different treatment patterns.

Results: The study included 482 patients: 222 (46.1%) received chemoradiotherapy, 58 (12.0%) underwent radiotherapy alone, 37 (7.7%) received chemotherapy alone, 50 (10.4%) underwent surgery, and 115 (23.8%) received no treatment. Median CSS were 12, 4, 6, 18, and 1 month for chemoradiotherapy, radiotherapy alone, chemotherapy alone, surgery, and non-treatment groups. Median OS for these groups were 11, 3, 6, 17, and 1 month, respectively. Multivariable proportional hazard regression analysis revealed that patients who underwent surgery experienced significantly improved CSS (hazard ratio [HR] = 0.42, 95% confidence interval [CI]: 0.24-0.72; P = 0.002) and OS (HR = 0.45, 95% CI: 0.28-0.74; P = 0.002) compared to those receiving chemoradiotherapy after propensity score matching.

Conclusions: Esophagectomy, with or without radiotherapy and/or chemotherapy, results in better survival outcomes than chemoradiotherapy in patients with stage T4b esophageal cancer.

Keywords: T4b; esophageal cancer; survival; treatment patterns.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST: The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Flowchart illustrating the process of patient selection. SCC: squamous cell carcinoma. AC: adenocarcinoma.
Figure 2
Figure 2
Survival between treatment patterns. (A) Cancer-specific survival. (B) Overall survival.
Figure 3
Figure 3
Multivariate regression analysis of prognostic factors. (A) Cancer-specific survival. (B) Overall survival. SCC: squamous cell carcinoma. AC: adenocarcinoma.
Figure 4
Figure 4
Survival between chemoradiotherapy and surgery groups after propensity score matching. (A) Cancer-specific survival. (B) Overall survival.
Figure 5
Figure 5
Multivariate regression analysis of prognostic factors after propensity score matching. (A) Cancer-specific survival. (B) Overall survival. SCC: squamous cell carcinoma. AC: adenocarcinoma.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71:209–49. 10.3322/caac.21660 - DOI - PubMed
    1. Zhu H, Ma X, Ye T, Wang H, Wang Z, Liu Q, Zhao K. Esophageal cancer in China: Practice and research in the new era. Int J Cancer. 2023; 152:1741–51. 10.1002/ijc.34301 - DOI - PubMed
    1. Okines AF, Cunningham D. Multimodality treatment for localized gastro-oesophageal cancer. Ann Oncol. 2010; 21 Suppl 7:vii286–93. 10.1093/annonc/mdq282 - DOI - PubMed
    1. Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet. 2017; 390:2383–96. 10.1016/S0140-6736(17)31462-9 - DOI - PubMed
    1. Lordick F, Mariette C, Haustermans K, Obermannová R, Arnold D, and ESMO Guidelines Committee. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016; 27:v50–7. 10.1093/annonc/mdw329 - DOI - PubMed

Publication types